Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.47 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 5/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30083733 | 0.87 | PKM (0.43) | CYP1A2ALDH1A1CYP3A4TRPV4ERN1 | |
| SCHEMBL28340937 | 0.83 | ACHE (0.48) | ALDH1A1TRPV4ERN1MAPK1USP2 | |
| SCHEMBL15412164 | 0.82 | CA12 (0.37) | CYP1A2ALDH1A1CYP3A4TRPV4ERN1 | |
| SCHEMBL26490138 | 0.81 | MAPK1 (0.41) | CYP1A2ALDH1A1CYP3A4TRPV4ERN1 | |
| SCHEMBL24866446 | 0.81 | TRPV4 (0.43) | ALDH1A1TRPV4ERN1MAPK1SMN1; SMN2 | |
| SCHEMBL30083747 | 0.81 | TRPV4 (0.43) | ALDH1A1TRPV4MAPK1USP2SMN1; SMN2 | |
| SCHEMBL31650218 | 0.79 | SMN1; SMN2 (0.47) | ALDH1A1TRPV4ERN1MAPK1SMN1; SMN2 | |
| SCHEMBL115788 | 0.78 | ERN1 (0.48) | CYP1A2ALDH1A1CYP3A4ERN1CA12 | |
| SCHEMBL4469024 | 0.78 | ALDH1A1 (0.42) | CYP1A2ALDH1A1CYP3A4TRPV4CYP1A1 | |
| SCHEMBL152815 | 0.78 | RAPGEF4 (0.46) | CYP1A2ALDH1A1CYP3A4TRPV4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110627832-A | Preparation method for synthesizing tenofovir alafenamide by oxidation method | 江西农业大学 | 2019-12-31 | — | — | CN | claimed |
| CN-117209426-B | Nitidine-like sulfonamide derivative and preparation method and application thereof | 广西中医药大学 | 2026-05-19 | — | — | CN | disclosed |
| US-20260062406-A1 | Benzisoxazole Sulfonamide Derivatives | PFIZER (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4299135-B1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER (US) | 2025-08-06 | — | — | EP | disclosed |
| US-12371425-B2 | Benzisoxazole sulfonamide derivatives | PFIZER INC. (US) | 2025-07-29 | — | — | US | disclosed |
| EP-3986890-B9 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER (US) | 2025-04-16 | — | — | EP | disclosed |
| CN-114364672-B | Benzisoxazole sulfonamide derivatives | 辉瑞大药厂 | 2024-09-06 | — | — | CN | disclosed |
| EP-4299135-A2 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | Pfizer Inc. (US) | 2024-01-03 | — | — | EP | disclosed |
| CN-117209426-A | Nitidine-like sulfonamide derivative and preparation method and application thereof | 广西中医药大学 | 2023-12-12 | — | — | CN | disclosed |
| EP-3986890-B1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-1113005-A1 | Sulfonium salt compounds | Wako Pure Chemical Industries, Ltd. (JP) | 2001-07-04 | — | — | EP | disclosed |
| US-4487726-A | USED IN SYNTHESIS OF PEPTIDES CONTAINING GAUNIDING GROUP | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1984-12-11 | — | — | US | disclosed |
| EP-0033976-B1 | METHOD FOR PROTECTING GUANIDINO GROUP AND RESTORING THE SAME | Takeda Chemical Industries, Ltd. (JP) | 1984-05-30 | — | — | EP | disclosed |
| EP-0056274-B1 | INDOLE DERIVATIVES AND A METHOD FOR PRODUCTION OF PEPTIDES | Takeda Chemical Industries, Ltd. (JP) | 1984-05-09 | — | — | EP | disclosed |
| US-4416820-A | Indole derivatives and a method for production of peptides | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1983-11-22 | — | — | US | disclosed |
| US-4368150-A | WITH A BENZENESULFONYL COMPOUND | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1983-01-11 | — | — | US | disclosed |
| EP-0056274-A1 | Indole derivatives and a method for production of peptides | Takeda Chemical Industries, Ltd. (JP) | 1982-07-21 | — | — | EP | disclosed |
| EP-0033976-A2 | Method for protecting guanidino group and restoring the same | Takeda Chemical Industries, Ltd. (JP) | 1981-08-19 | — | — | EP | disclosed |
| US-4218476-A | Anti-thrombotic N-alkylthioakylamino benzenesulfonamides | AB KABI (SE) | 1980-08-19 | — | — | US | disclosed |
| EP-0000826-A1 | Diorthosubstituted benzene derivatives, especially for use in a method of therapy, processes for their preparation, and pharmaceutical compositions containing them | Kabi AB (SE) | 1979-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371425-B2 | Benzisoxazole sulfonamide derivatives | BRIX1, RB1, BCR | CYP1A2 858/4885ALDH1A1 550/4885CYP3A4 909/4885 |
| US-20260062406-A1 | Benzisoxazole Sulfonamide Derivatives | KAT8, KAT5, KAT7 | CYP1A2 1605/4885ALDH1A1 1927/4885CYP3A4 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.